The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
- Sponsor
- Rigmor Højland Jensen
- Study ID
- NCT06027567
- Phase
- PHASE4
- Status
- Completed
Conditions
- Idiopathic Intracranial Hypertension
- Intracranial Pressure
- Obesity
- Papilledema
- Pseudotumor Cerebri Syndrome
- Weight Loss
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Semaglutide — DRUGSubcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg
- Very Low Calorie Diet — DIETARY_SUPPLEMENTVery Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products
- Dietician counselling — BEHAVIORALCounselling by a dietician on weight loss through behavioural changes and life style intervention
Study Details
50 patients with verified new-onset Idiopathic Intracranial Hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with Semaglutide for 10 months combined, in the initial 8 weeks following diagnosis, with a Very Low Calorie-Diet (max 800 kcal/day)
Key Dates
- Start date
- Sep 2, 2022
- Status verified
- Oct 2025
- Primary completion
- Jan 28, 2025
- Completion
- Oct 28, 2025
Study Design
- Enrollment
- 38 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: SemaglutideSemaglutide up-titration to 2.4 mg for 10 months initially combined with a Very Low Calorie Diet (800 kcal/day) for 8 weeks. Counselling by dietician Standard medical treatment of intracranial hypertension
- Active Comparator: Standard care (dietician)Standard weight loss intervention Counselling by dietician Standard medical treatment of intracranial hypertension
Primary Outcome Measure
Weight [ Time Frame: 8 weeks ]
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia